Active, not recruiting
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
NCT04675710
- Conditions
- Carcinoma, Neoplasms, Neoplasms by Histologic Type, +4 more
- Locations
-
- Stanford School of Medicine Stanford, California, United States
- University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Minnesota, United States
- Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio, United States